Market Intelligence, Clinical Progress, and High-Purity Reagents for Transcription Machinery Inhibition, Synthetic Lethality, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for POLR2D drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | POLR2D Recombinant / Mutant Protein; Full-length, E. coli or HEK293 expressed; Sequence Verified; High Purity (>95%); Endotoxin <1 EU/µg; Theoretical MW ~17 kDa. | View POLR2D Products |
| Gene Delivery | POLR2D Promise-ORF / Lentivirus; Full-length ORF for stable cell lines; CMV promoter, Puromycin selection. | View POLR2D Products |
| Benchmark Ab | Anti-POLR2D (RPB4) Recombinant Antibody; Sequence-defined positive control for Western Blot, IP, and ChIP applications. | View POLR2D Products |
| Complex Formation | POLR2E Recombinant Protein; Binding partner for heterodimer (RPB4/RPB7) assays. | View POLR2E Products |
| Validator | POLR2D siRNA Set (3 Unique Targets); For knockdown verification and specificity controls in transcriptional assays. | View POLR2D Products |
| Related Target A | POLR2A (RPB1); Largest catalytic subunit of RNA Pol II; direct target of elongation toxins and CDK substrates. | View POLR2A Products |
| Related Target B | CDK7; CDK-activating kinase that phosphorylates POLR2A CTD; synergistic transcriptional blockade partner. | View CDK7 Products |
| Related Target C | CDK9 (P-TEFb); Regulates RNA Pol II elongation; synergistic inhibition with POLR2D targeting. | View CDK9 Products |
| Related Target D | MYC; Major oncogenic driver causing transcriptional addiction; target for synthetic lethality with POLR2D. | View MYC Products |
| Related Target E | POLR2E (RPB7); Forms stable heterodimer with POLR2D; critical for PPI inhibitor assays and complex reconstitution. | View POLR2E Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Biophysical binding & structural studies | High-purity full-length POLR2D (>95%) with theoretical MW ~17 kDa; endotoxin controlled for SPR/ITC. |
| Reconstituted RNA Pol II complex assembly | Sequence-verified POLR2D with optional affinity tags (His, GST) for pull-down and multi-subunit reconstitution. |
| Cellular target engagement & rescue | POLR2D Lentivirus ORF and siRNA set included for CETSA rescue and specificity checks. |
| Cross-species ortholog evaluation | Human / Mouse / Cyno ortholog proteins available; sequence verified by mass spec for translational assays. |
| Sub-family selectivity (Pol I vs Pol II vs Pol III) | Homolog Panel: POLR2D, POLR1D, POLR3D proteins strictly verified by N-terminal sequencing. |
| PPI interface mapping (POLR2D/E heterodimer) | High-purity human/mouse ortholog proteins (>95% by SDS-PAGE); sequence verified by mass spec; lyophilized format for stability. |
Live POLR2D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Synthetic Lethality Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for POLR2D therapeutics is emerging from CRISPR-Cas9 dependency screens, with academic consortia identifying it as a vulnerability in transcriptionally addicted malignancies. The field is shifting from broad cytotoxic agents to targeted synthetic lethality, subunit-specific protein–protein interaction (PPI) disruption, and precision degrader modalities. First-generation approaches include siRNA/ASO, PROTACs, and small molecules that disrupt the POLR2D-POLR2E interface. Next-wave R&D targets synthetic lethality combinations with CDK7 and CDK9 inhibitors to achieve complete transcriptional shutdown while sparing normal cells. As resistance mechanisms emerge, demand for mutant protein panels and cross-species orthologs will grow significantly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Emerging academic consortia; biotech startups | Small cell lung cancer, transcription-addicted tumors | Heterodimer formation assay (Need POLR2D + POLR2E proteins for SPR/BLI) |
| PROTAC / Degrader | Preclinical biotech, academic spinoffs | Solid tumors (synthetic lethality); MYC-driven cancers | Degradation assay (Need high-purity POLR2D proteins & Lentivirus cell lines for ternary complex & cellular degradation) |
| Peptide / Degrader | Preclinical translational groups | MYC-driven cancers | Ternary complex formation (Need mutant vs WT POLR2D panel) |
| siRNA / ASO | Academic CRISPR consortia; oligonucleotide therapeutics companies | Solid tumors (transcription addiction); genomically defined cancers | Knockdown validation (Need Lentivirus ORF rescue + siRNA controls) |
| ADC Payload (Amanitin) | Heidelberg Pharma | Various oncology indications | Mechanism validation (RNA Pol II inhibition assays) |